Omnes Capital's investments
Pherecydes Pharma SA specializes in research into innovative and adaptive solutions to fight multi-resistant bacterial infections, using cocktails of natural phages.
Thanks to its unique expertise, Pherecydes Pharma has managed to develop a large bank of bacteriophages cocktails to fight antibiotic-resistant infections, steadily on the rise since the 1980s.
Founded in 2016, Octimet Oncology N.V. (Belgium) is a new company (spin-off from Johnson & Johnson) that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio.
European Games Group
The company specialises in monetising and marketing cross-platform video games that run on mobiles, tablets, Facebook or web browsers. The company has built up a substantial portfolio of games, including the highly popular Hero Zero by developer Playata. Hero Zero has signed up more than 17 million users and ranked as the eighth most searched-for game in Brazil during 2013, coming in ahead of AAA titles such as PES 2014.
Greenbureau is the first free-of-charge confidential and secure internet service that centralises bills for consumers. A pioneer of multi-brand digital customer relationships, Greenbureau saves on running costs for large groups by switching their customers over to digital billing, invoicing and online account management, etc.
Tree Digital Factory
Mister Bell joind the Tree Digital Factory Group.
Mister Bell is a mobile performance based mobile advertising network founded in 2010.
With an exclusive inventory and unprecedented distribution capacity, Mister Bell is establishing itself as one of the leaders in mobile performance in Europe, Latin America and the Middle East. With its proprietary advertising tracking and re-targeting systems on smartphones and tablets, Mister Bell guarantees ROI levels to advertisers and offers innovative monetisation systems to content providers. Mister Bell is headquartered in Paris and now has subsidiaries in London, Berlin and Rio.
Progexia is an alternative operator serving private health insurance companies, wich provide solutions in the Cloud for reduce benefits payments costs.
Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.
A long-term view
Alexia Perouse (Partner at Omnes Capital) and Bernard Gilly first discussed vision restoration systems in the early 2000s. "VRSs aim to enable blind people to perceive shapes and movements, a really tremendous project. But their design came up against two hurdles, systems miniaturisation and real-time image transmission", explains Bernard Gilly.
Pixium overcame these hurdles in 2011 when it launched IRIS (short for Intelligent Retinal Implant System), consisting of a pair of glasses with an integrated mini-camera linked to a pocket computer and a retinal implant that stimulates the brain cells.
"It met all our criteria for investment: disruptive technology, a seasoned management team and a promising medtech sector", says Alexia Perouse. So in 2012, Omnes Capital invested €5 million.